A5065467914- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Heart Failure Treatment and Management
- Cardiac Health and Mental Health
- Healthcare cost, quality, practices
- Diabetes Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Disease and Adiposity
- Lipoproteins and Cardiovascular Health
- Liver Disease Diagnosis and Treatment
- Cardiac Arrhythmias and Treatments
- Ion channel regulation and function
- Clinical practice guidelines implementation
- Diet and metabolism studies
- Cardiovascular Effects of Exercise
- Meta-analysis and systematic reviews
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cardiac tumors and thrombi
- Vascular Procedures and Complications
- Cerebrovascular and Carotid Artery Diseases
Amsterdam University Medical Centers
2020-2024
University of Amsterdam
2020-2024
Amsterdam UMC Location University of Amsterdam
2021-2024
Baylor College of Medicine
2023
Early P2Y
Abstract Aims/hypothesis Obesity is a major risk factor for type 2 diabetes. However, body composition differs between women and men. In this study we investigate the association diabetes status whether moderated by sex. Methods population-based cohort ( n =7639; age 40–75 years, 50% women, 25% diabetes), estimated sex-specific associations, differences therein, of prediabetes (i.e. impaired fasting glucose and/or tolerance) (reference: normal metabolism [NGM]) with dual-energy x-ray...
Objectives To validate the Global Registry of Acute Coronary Events (GRACE) risk score and examine extent impact risk–treatment paradox in contemporary patients with acute coronary syndrome (ACS). Methods Data from 5015 ACS enrolled FORCE-ACS registry between January 2015 December 2019 were used for model validation. The performance GRACE predicting in-hospital 1-year mortality was evaluated based on indices discrimination calibration. Differences delivery guideline-recommended care among...
Acute coronary syndrome (ACS) is frequently accompanied by newly diagnosed atrial fibrillation (AF).
Spontaneously depolarizing nodal cells comprise the pacemaker of heart. Intracellular calcium (Ca
Diagnostic and treatment strategies for acute coronary syndrome have improved dramatically over the past few decades, but mortality recurrent myocardial infarction rates remain high. An aging population with increasing co-morbidities heralds new clinical challenges. Therefore, in order to evaluate improve current strategies, detailed information on presentation, follow-up real-world patients is needed. The Future Optimal Research Care Evaluation Acute Coronary Syndrome (FORCE-ACS) registry...
Early aspirin withdrawal, also known as P2Y12-inhibitor monotherapy, following percutaneous coronary intervention (PCI) for non-ST-segment elevation acute syndrome (NSTE-ACS) can reduce bleeding without a trade-off in efficacy. Still the average daily risk is highest during first months and it remains unclear if be omitted immediately PCI.The LEGACY study an open-label, multicenter randomized controlled trial evaluating safety efficacy of immediate monotherapy versus dual antiplatelet...
Abstract Background CYP2C19 genotype-guided de-escalation from ticagrelor or prasugrel to clopidogrel, may optimize the balance between ischemic and bleeding risk in ACS patients. Purpose Compare event rates genotyped patients versus standard care. Methods Since 2015, FORCE-ACS registry received dual antiplatelet therapy (DAPT). 2021, immediate P2Y12-inhibitor was applied, switching non-carriers of loss-of-function allele CYP2C19*3 CYP2C19*2 while carriers, carrying at least one allele,...
A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function allele from ticagrelor or prasugrel to clopidogrel, has shown reduce bleeding risk affecting effectivity of therapy by increasing ischemic risk. We estimated the cost-effectiveness this personalized approach compared standard dual antiplatelet (DAPT; aspirin plus ticagrelor/prasugrel) in Netherlands.
Graphical AbstractClinical outcomes and treatment adherence during 12 months follow-up. *Second bleeding event in same patient. PCI, percutaneous coronary intervention; TVR, target vessel revascularization.
Abstract Background Patients with acute coronary syndrome (ACS) and extreme body weights exhibit varying risks of bleeding thrombotic outcomes. Furthermore, can influence the pharmacodynamic response to potent P2Y12 inhibitors (ticagrelor/prasugrel) clopidogrel. Purpose This study aims assess impact on cardiovascular outcomes, as well comparative efficacy safety versus Methods Data was extracted from FORCE-ACS registry, a prospective, multicentre, enrolling patients ACS. were stratified (in...
Aims Patients presenting with acute coronary syndrome (ACS) are frequently treated the P2Y12-inhibitor ticagrelor. Some patients prematurely discontinue ticagrelor, but incidence of reasons for and clinical implications treatment modification relatively unknown. Methods Results Data from 4,278 ACS (mean age: 63.6 years, 26.1% women) who were discharged on ticagrelor enrolled in FORCE-ACS registry between 2015 2020 used. Treatment modifications categorized as physician-recommended...
Abstract Background The use of risk scores to guide the duration dual antiplatelet therapy(DAPT) in patients with acute coronary syndrome(ACS) is recommended current guidelines, however clinical data on impact its prospective lacking. Purpose To compare risk-score guided DAPT standard care ACS patients. Methods Since 2015, are enrolled FORCE-ACS registry. In 2018, we implemented a score-guided approach for duration. this analysis, compared which was by bleeding and ischemic assessment using...
Patients with acute coronary syndrome (ACS) remain at high risk for recurrent ischaemic and bleeding events during follow-up. Our study aimed to quantify compare the impact of these adverse on quality life (QoL). Data from patients ACS prospectively enrolled in FORCE-ACS registry between January 2015 December 2019 were used this study. The primary interest hospital readmission Bleeding Academic Research Consortium type 2 or 3 12 months QoL was measured using EQ-5D Visual Analogue Scale (VAS)...
Cangrelor is the first and only intravenous P2Y
Abstract Background Acute coronary syndrome (ACS) patients at high risk might benefit most from guideline-recommended interventions. However, it is well recognized that the delivery of guideline-directed care inversely related to estimated mortality risk, so called risk-treatment paradox. Purpose To assess existence paradox in a contemporary cohort ACS and its possible association with one-year mortality. Methods The study population consisted enrolled FORCE-ACS registry who survived their...
Abstract Background/Introduction Newly diagnosed atrial fibrillation (AF) frequently occurs during acute coronary syndrome (ACS). In contrast to known AF, little is about the prognostic and therapeutic implications of new AF. Purpose To evaluate impact newly AF in patients with ACS. Furthermore, we evaluated association episode characteristics clinical outcomes: early vs late occurrence, short long duration, post-CABG OAC treatment. Methods This analysis was performed within prospective,...